Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_assertion type Assertion NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_head.
- NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_assertion description "[Retrospective studies have demonstrated that nearly 50% of patients with ovarian cancer with normal cancer antigen 125 (CA125) levels have persistent disease; however, prospectively distinguishing between patients is currently impossible.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_provenance.
- NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_assertion evidence source_evidence_literature NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_provenance.
- NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_assertion SIO_000772 24563622 NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_provenance.
- NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_assertion wasDerivedFrom befree-20150227 NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_provenance.
- NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_assertion wasGeneratedBy ECO_0000203 NP962795.RAzQxQo3m6k0NIGGpYD9cBEvZm77EenIRgeUSD85PyKaQ130_provenance.